A Prospective, Multi-institutional, Pathologist-Based Assessment of 4 Immunohistochemistry Assays for PD-L1 Expression in Non–Small Cell Lung Cancer-Reference-Cited by-同舟云学术

A Prospective, Multi-institutional, Pathologist-Based Assessment of 4 Immunohistochemistry Assays for PD-L1 Expression in Non–Small Cell Lung Cancer

Published:2017-08-01 Issue:8 Volume:3 Page:1051
ISSN:2374-2437
Container-title:JAMA Oncology
language:en
Short-container-title:JAMA Oncol

Author:

Rimm David L.¹,Han Gang²,Taube Janis M.³,Yi Eunhee S.⁴,Bridge Julia A.⁵,Flieder Douglas B.⁶,Homer Robert¹,West William W.⁵,Wu Hong⁶,Roden Anja C.⁴,Fujimoto Junya⁷,Yu Hui⁸,Anders Robert³,Kowalewski Ashley⁸,Rivard Christopher⁸,Rehman Jamaal⁹,Batenchuk Cory¹⁰,Burns Virginia¹⁰,Hirsch Fred R.⁸,Wistuba Ignacio I.⁷

Affiliation:

1. Department of Pathology, Yale University School of Medicine, New Haven, Connecticut

2. Department of Epidemiology and Biostatistics, Texas A&M University School of Public Health, College Station

3. Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland

4. Department of Anatomic Pathology, Mayo Clinic, Rochester, Minnesota

5. Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha

6. Department of Pathology, Fox Chase Cancer Center, Philadelphia, Pennsylvania

7. Department of Translational Molecular Pathology, The University of Texas M.D. Anderson Cancer Center, Houston

8. Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora

9. Department of Pathology, NorthShore University Health System, Evanston, Illinois

10. Department of Immuno-Oncology, Bristol-Myers Squibb, Plainsboro, New Jersey

Publisher

American Medical Association (AMA)

Subject

Oncology,Cancer Research

Cited by 658 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Brightfield Multiplex Immunohistochemistry Assay for PD-L1 Evaluation in Challenging Melanoma Samples;Applied Immunohistochemistry & Molecular Morphology;2024-08-21

2. Prognostic implications, genomic and immune characteristics of lung adenocarcinoma with lepidic growth pattern;Journal of Clinical Pathology;2024-08-03

3. Neoadjuvant Chemotherapy and Immunotherapy for Estrogen Receptor–Positive Human Epidermal Growth Factor 2–Negative Breast Cancer;Journal of Clinical Oncology;2024-08-01

4. Differential Abundance of DNA Damage Sensors and Innate Immune Signaling Proteins in Inositol Polyphosphate 4-Phosphatase Type II–Negative Triple-Negative Breast Cancer Classified by Immunotype;The American Journal of Pathology;2024-08

5. Multi-Tissue Controls and Multiplex Immunocytochemistry in Pulmonary Cytology;Acta Cytologica;2024-07-30